BiotechTube
Home/Pipeline/Parkinson's Disease Therapy

Parkinson's Disease Therapy

Parkinson's Disease

Phase 2Active

Key Facts

Indication
Parkinson's Disease
Phase
Phase 2
Status
Active
Company
InnoMedica

About InnoMedica

InnoMedica is a private, clinical-stage biotech leveraging a proprietary nanotechnology platform for targeted drug delivery. Its most advanced program is a potentially novel therapy for Parkinson's disease, which is in Phase II clinical development, with a parallel oncology program demonstrating the platform's versatility. The company has established its own GMP-certified manufacturing facility ('Nanofactory') in Switzerland and is currently executing a capital increase round to fund development through 2025.

View full company profile

Therapeutic Areas

NeurologyOncology

Other Parkinson's Disease Drugs

DrugCompanyPhase
NPT200-11Neuropore TherapiesPhase 1
NUZ-001Neurizon TherapeuticsPreclinical
VXX-301VaxxinityPreclinical
BAN2802BioArcticPhase 1
CNM-Au8ClenePhase 2
hpSC-Derived Neural/Dopaminergic CellsInternational Stem CellPreclinical/Early Clinical
SLS-004Seelos TherapeuticsPreclinical
SLS-007Seelos TherapeuticsPreclinical
Parkinson's Disease Portfolio (Platform-derived)WD PharmaceuticalNot Disclosed (Likely Preclinical/Early Clinical)
UX-DA001UniXellPhase 1
Parkinson's Disease ResearchProgenaBiomeResearch
A9 Dopaminergic Neuron TherapyTrailhead BiosystemsPre-clinical